3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Leukemia, Myeloid, Acute
32
Myelodysplastic Syndromes
21
Leukemia, Myelomonocytic, Chronic
12
Myeloproliferative Disorders
4
Triple Negative Breast Neoplasms
2
Myelodysplastic-Myeloproliferative Diseases
2
Leukemia, Biphenotypic, Acute
2
Anemia, Refractory, with Excess of Blasts
2
Thrombocythemia, Essential
1
Systemic Mastocytosis With an Associated Hematologic Neoplasm
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Patient Preference
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Chronic-Phase
1
Hodgkin Disease
1
GATA2 Deficiency
1
Cytopenia
1
Interventions
lutetium Lu 177 dotatate
34
Everolimus
33
lanreotide
13
gallium Ga 68 dotatate
13
Temozolomide
13
Magnetic Resonance Spectroscopy
13
Nivolumab
12
pembrolizumab
11
Octreotide
11
Capecitabine
11
177Lu-octreotide, DOTA(0)-Tyr(3)-
10
cabozantinib
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
surufatinib
8
Sunitinib
8
Specimen Handling
7
Carboplatin
7
pasireotide
6
amino-acid, glucose, and electrolyte solution
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
Lutetium-177
5
Ipilimumab
5
Fluorodeoxyglucose F18
5
Etoposide
5
Cisplatin
5
Bevacizumab
5
telotristat ethyl
4
olaparib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neuroendocrine Tumors
×
decitabine and cedazuridine drug combination
×
Clear all
NCT05178693
2025-11-24
LANTana
Imperial College London
Phase 1
Recruiting
27 enrolled